SPEAKERS

KEYNOTE SPEAKER: P. Roy Vagelos

PANEL DISCUSSION I: IMPACT OF PRICING AND POLICY ON THE NEXT DECADE OF THERAPEUTIC INNOVATION
Jeff Berkowitz – CEO, Real Endpoints
Anna Kaltenboeck – Director, Drug Pricing Lab, Memorial Sloan Kettering Cancer Center
Steve Sands – Vice Chairman Investment Banking and Chairman Global Healthcare Group, Lazard
Madelaine Feldman – President, Coalition of State Rheumatology Organizations, Chair of the Alliance for Safe Biologic Medicines and head of Government Affairs for the Rheumatology Alliance of Louisiana
MODERATOR: Molly Williams – Pfizer

PANEL DISCUSSION II: HOW ARTIFICIAL INTELLIGENCE IS SHAPING THE BIOPHARMA INDUSTRY’S THERAPEUTIC PIPELINE
Paolo Guarnieri – Principal Scientist, Boehringer Ingelheim
Sarah Kramarz – Director of Business Development at Flatiron Health
Manuel Ferreira – Director of Statistical Genetics, Regeneron
Karen Akinsanya – Chief Biomedical Scientist, Schrodinger
Ramesh Durvasula – VP and Information Officer, Research Labs at Eli Lilly  *Invited
MODERATOR: Jessica Lin – Vice President Life Sciences, EY – Parthenon  (Ernst & Young)

PANEL DISCUSSION III: ROLE OF FOUNDATIONS IN DRIVING TRANSLATIONAL MEDICINE AND CLINICAL DEVELOPMENT
Lynn O’Connor Vos – CEO, Muscular Dystrophy Association
Louis  DeGennaro – CEO, Leukemia and Lymphoma Society
Todd Sherer, PhD – CEO, Michael J Fox Foundation
Laurie Churchill – Program Officer, Crohn’s Disease Program, Helmsley Charitable Trust
MODERATOR: Linda Malek – Moses & Singer

PANEL DISCUSSION IV: FRONTIERS IN LONGEVITY AND AGING SCIENCE
Mehmood Khan – CEO Life Biosciences
Randy Klein – CEO, HomeTeam
Howard Fillit – Founding Executive Director and Chief Science Officer, The Alzheimer’s Drug Discovery Foundation and Clinical Professor of Geriatric Medicine, Palliative Care and Neuroscience, The Icahn School of Medicine at Mount Sinai
MODERATOR: Sree Kant – Head of Business Development, Life Biosciences

*Schedule subject to change.